We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?
Read MoreHide Full Article
Key Takeaways
Incyte's rally reflects strong demand for Jakafi, Opzelura, Niktimvo, Monjuvi/Minjuvi and Zynyz.
Opzelura's CMS agreement could add $300-$310 million to 2026 net sales.
Pipeline progress and planned launches support growth, but Vega costs pressure 2026 earnings estimates.
Shares of Incyte (INCY - Free Report) have rallied 23% year to date compared with the industry’s growth of 5.2%. The stock has also outperformed the medical sector and the S&P 500 Index during this time frame.
Much of this rally came after the company reported strong second-quarter results on July 28. Importantly, growth was supported by demand across multiple products, including Jakafi, Opzelura, Niktimvo, Monjuvi/Minjuvi and Zynyz.
The stock hit a 52-week high of $132.60 following the announcement.
Investors’ optimism around the company’s recent regulatory updates and encouraging pipeline progress has also aided the stock’s year-to-date outperformance.
INCY Outperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
Against this backdrop, a closer evaluation of the company’s strengths and weaknesses can help assess its attractiveness as an investment opportunity.
Opzelura’s Strong Performance Boosts INCY
Opzelura (ruxolitinib) cream, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved in the United States for nonsegmental vitiligo in patients aged 12 and older, making it the first and only FDA-approved repigmentation treatment. It is also approved for mild-to-moderate atopic dermatitis in patients aged two and older. In Europe, Opzelura is approved for nonsegmental vitiligo with facial involvement and moderate AD in adults.
The strong uptake of this drug has significantly boosted the top line.
Earlier in the year, Incyte reached an agreement with the Centers for Medicare & Medicaid Services (“CMS”) to resolve litigation concerning the application of Medicaid rebate rules to Opzelura cream.
Under the agreement, CMS will not apply the line extension regulation to Opzelura as if it were a line extension of lead drug Jakafi (ruxolitinib), prompting the company to withdraw its lawsuit challenging the rules.
As a result of the agreement with CMS, the total estimated incremental impact on Opzelura net sales for the full year 2026 is $300-$310 million, which includes the reversal of previously established accrual balances through the first quarter of 2026 and effects of an improved gross-to-net profile on a go-forward basis.
INCY’s Lead Drug Jakafi Maintains Momentum
At present, Incyte’s lead drug Jakafi accounts for the majority of its revenues.
The lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older.
Sales in all indications continue to be strong and should maintain momentum going forward.
In May, the FDA approved Jakafi XR (extended-release) for the same indications as Jakafi.
The drug is marketed by Incyte in the United States and by Novartis (NVS - Free Report) as Jakavi in ex-U.S. markets.
Incyte earns product royalty revenues from Novartis for the commercialization of Jakavi in ex-U.S. markets.
Novartis also has exclusive worldwide development and commercialization rights to Tabrecta.
INCY’s Recent Pipeline Progress
Incyte’s efforts to develop new drugs to diversify its portfolio and add an incremental stream of revenues are impressive.
Encouraging uptake of new drugs like Pemazyre and Monjuvi also contributes to its top-line growth.
Positive phase III frontMIND data for Monjuvi/Minjuvi could expand its opportunity into first-line DLBCL, with a potential U.S. launch in the first quarter of 2027.
Incyte recently strengthened its hematology franchise through the acquisition of Vega Therapeutics, adding latarcibart, a potentially transformative therapy for von Willebrand disease, to its pipeline. Latarcibart is currently in phase III development. Incyte is also building a deeper late-stage pipeline. Programs such as INCA033989, povorcitinib, INCB161734 and INCB123667 provide additional potential growth drivers.
With 10 data readouts expected in the second half of 2026 and several product launches planned through early 2027, Incyte is well positioned to enter its next phase of growth.
Valuation & Estimates
Going by the price/earnings ratio, INCY seems to be fairly priced. INCY’s shares currently trade at 16.33X forward earnings, higher than its mean of 16.24X but lower than 17.66X for the large-cap pharma biotech industry.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share (EPS) has plunged to $3.70 from $6.61 over the past 60 days. During the same time frame, the EPS estimate for 2026 has jumped 16 cents to $9.01.
The decline in 2026 EPS estimates is primarily due to upfront costs related to the acquisition of Vega Therapeutics, which will be recognized as an in-process research and development (IPR&D) expense, affecting both third-quarter and full-year 2026 results.
Image Source: Zacks Investment Research
Stay Invested in INCY
Incyte’s strong commercial portfolio, improving demand across key products and encouraging pipeline progress support its long-term growth outlook. Opzelura’s expanding sales opportunity, continued strength in Jakafi, potential label expansion for Monjuvi/Minjuvi and multiple late-stage pipeline programs provide several avenues for revenue growth.
However, much of this optimism appears to be already priced into INCY’s valuation. The sharp decline in 2026 EPS estimates following the Vega Therapeutics acquisition highlights near-term earnings pressure from higher IPR&D and operating expenses. INCY also remains heavily dependent on Jakafi, which faces the risk of generic competition over time.
Competition has increased for some of Jakafi’s approved indications. GSK plc’s (GSK - Free Report) Ojjaara, which is also approved for the treatment of intermediate- or high-risk myelofibrosis (MF), including primary MF and secondary MF (post-polycythemia vera and post-essential thrombocythemia) in adults with anemia, poses competition.
Hence, we recommend existing shareholders to stay invested while prospective investors may wait for a more attractive entry point.
View the Zacks #1 Rank List
Image: Bigstock
INCY Stock Gains 23% Year to Date: Buy, Sell or Hold?
Key Takeaways
Shares of Incyte (INCY - Free Report) have rallied 23% year to date compared with the industry’s growth of 5.2%. The stock has also outperformed the medical sector and the S&P 500 Index during this time frame.
Much of this rally came after the company reported strong second-quarter results on July 28. Importantly, growth was supported by demand across multiple products, including Jakafi, Opzelura, Niktimvo, Monjuvi/Minjuvi and Zynyz.
The stock hit a 52-week high of $132.60 following the announcement.
Investors’ optimism around the company’s recent regulatory updates and encouraging pipeline progress has also aided the stock’s year-to-date outperformance.
INCY Outperforms Industry, Sector and S&P 500 Index
Image Source: Zacks Investment Research
Against this backdrop, a closer evaluation of the company’s strengths and weaknesses can help assess its attractiveness as an investment opportunity.
Opzelura’s Strong Performance Boosts INCY
Opzelura (ruxolitinib) cream, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, is approved in the United States for nonsegmental vitiligo in patients aged 12 and older, making it the first and only FDA-approved repigmentation treatment. It is also approved for mild-to-moderate atopic dermatitis in patients aged two and older. In Europe, Opzelura is approved for nonsegmental vitiligo with facial involvement and moderate AD in adults.
The strong uptake of this drug has significantly boosted the top line.
Earlier in the year, Incyte reached an agreement with the Centers for Medicare & Medicaid Services (“CMS”) to resolve litigation concerning the application of Medicaid rebate rules to Opzelura cream.
Under the agreement, CMS will not apply the line extension regulation to Opzelura as if it were a line extension of lead drug Jakafi (ruxolitinib), prompting the company to withdraw its lawsuit challenging the rules.
As a result of the agreement with CMS, the total estimated incremental impact on Opzelura net sales for the full year 2026 is $300-$310 million, which includes the reversal of previously established accrual balances through the first quarter of 2026 and effects of an improved gross-to-net profile on a go-forward basis.
INCY’s Lead Drug Jakafi Maintains Momentum
At present, Incyte’s lead drug Jakafi accounts for the majority of its revenues.
The lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea; intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF in adults; steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients 12 years and older; and chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients aged 12 years and older.
Sales in all indications continue to be strong and should maintain momentum going forward.
In May, the FDA approved Jakafi XR (extended-release) for the same indications as Jakafi.
The drug is marketed by Incyte in the United States and by Novartis (NVS - Free Report) as Jakavi in ex-U.S. markets.
Incyte earns product royalty revenues from Novartis for the commercialization of Jakavi in ex-U.S. markets.
Novartis also has exclusive worldwide development and commercialization rights to Tabrecta.
INCY’s Recent Pipeline Progress
Incyte’s efforts to develop new drugs to diversify its portfolio and add an incremental stream of revenues are impressive.
Encouraging uptake of new drugs like Pemazyre and Monjuvi also contributes to its top-line growth.
Positive phase III frontMIND data for Monjuvi/Minjuvi could expand its opportunity into first-line DLBCL, with a potential U.S. launch in the first quarter of 2027.
Incyte recently strengthened its hematology franchise through the acquisition of Vega Therapeutics, adding latarcibart, a potentially transformative therapy for von Willebrand disease, to its pipeline. Latarcibart is currently in phase III development.
Incyte is also building a deeper late-stage pipeline. Programs such as INCA033989, povorcitinib, INCB161734 and INCB123667 provide additional potential growth drivers.
With 10 data readouts expected in the second half of 2026 and several product launches planned through early 2027, Incyte is well positioned to enter its next phase of growth.
Valuation & Estimates
Going by the price/earnings ratio, INCY seems to be fairly priced. INCY’s shares currently trade at 16.33X forward earnings, higher than its mean of 16.24X but lower than 17.66X for the large-cap pharma biotech industry.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for 2026 earnings per share (EPS) has plunged to $3.70 from $6.61 over the past 60 days. During the same time frame, the EPS estimate for 2026 has jumped 16 cents to $9.01.
The decline in 2026 EPS estimates is primarily due to upfront costs related to the acquisition of Vega Therapeutics, which will be recognized as an in-process research and development (IPR&D) expense, affecting both third-quarter and full-year 2026 results.
Image Source: Zacks Investment Research
Stay Invested in INCY
Incyte’s strong commercial portfolio, improving demand across key products and encouraging pipeline progress support its long-term growth outlook. Opzelura’s expanding sales opportunity, continued strength in Jakafi, potential label expansion for Monjuvi/Minjuvi and multiple late-stage pipeline programs provide several avenues for revenue growth.
However, much of this optimism appears to be already priced into INCY’s valuation. The sharp decline in 2026 EPS estimates following the Vega Therapeutics acquisition highlights near-term earnings pressure from higher IPR&D and operating expenses. INCY also remains heavily dependent on Jakafi, which faces the risk of generic competition over time.
Competition has increased for some of Jakafi’s approved indications. GSK plc’s (GSK - Free Report) Ojjaara, which is also approved for the treatment of intermediate- or high-risk myelofibrosis (MF), including primary MF and secondary MF (post-polycythemia vera and post-essential thrombocythemia) in adults with anemia, poses competition.
Hence, we recommend existing shareholders to stay invested while prospective investors may wait for a more attractive entry point.
INCY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.